PYC · ASX

PYC Therapeutics Limited (ASX:PYC)

AU$1.39

 -0.01 (-0.714%)
ASX:Live
27/12/2024 10:47:54 AM
Hammer Bearish HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PYC Overview

PYC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Weak

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About PYC

Website

PYC Therapeutics Limited

Telephone

61.8.6151.0992

Address

6 Verdun Street Harry Perkins Institute Nedlands, Western Australia (WA) 6009

Description

PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001, and is headquartered in Nedlands, Australia.

PYC Price Chart

Key Stats

Market Cap

AU$653.25M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.72 - 2.1

Trade Value (12mth)

AU$104,309.00

1 week

-3.45%

1 month

-30%

YTD

41.67%

1 year

28.79%

All time high

6.49

Key Fundamentals

EPS 3 yr Growth

68.70%

EBITDA Margin

N/A

Operating Cashflow

-$39m

Free Cash Flow Return

-70.70%

ROIC

-69.10%

Interest Coverage

-1,206.20

Quick Ratio

9.40

Other Data

Shares on Issue (Fully Dilluted)

408m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.11

PYC Announcements

Latest Announcements

Date Announcements

16 December 24

PYC Nominates Fourth Clinical Drug Candidate in PMS Program

×

PYC Nominates Fourth Clinical Drug Candidate in PMS Program

28 November 24

Polycystic Kidney Disease Program Investor Presentation

×

Polycystic Kidney Disease Program Investor Presentation

27 November 24

PYC to Progress Kidney Drug Candidate Into Human Trials

×

PYC to Progress Kidney Drug Candidate Into Human Trials

27 November 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

27 November 24

Notification regarding unquoted securities - PYC

×

Notification regarding unquoted securities - PYC

27 November 24

Notification of cessation of securities - PYC

×

Notification of cessation of securities - PYC

22 November 24

Presentation of RP11 Clinical Trial Data at APVRS 2024

×

Presentation of RP11 Clinical Trial Data at APVRS 2024

21 November 24

Completion of Share Consolidation

×

Completion of Share Consolidation

14 November 24

Share Consolidation and ASX Code

×

Share Consolidation and ASX Code

13 November 24

2024 AGM Chairman's Address and CEO Presentation

×

2024 AGM Chairman's Address and CEO Presentation

13 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

13 November 24

Update - Consolidation/Split - PYC

×

Update - Consolidation/Split - PYC

11 November 24

Consolidation/Split - PYC

×

Consolidation/Split - PYC

06 November 24

Annual General Meeting - Conference Call Details

×

Annual General Meeting - Conference Call Details

05 November 24

RP11 SRC Approves Dose Escalation to Final Patient Cohort

×

RP11 SRC Approves Dose Escalation to Final Patient Cohort

01 November 24

First ADOA Patient Dosed in Clinical Trial

×

First ADOA Patient Dosed in Clinical Trial

31 October 24

Presentation of RP11 Single Dose Data at RANZCO

×

Presentation of RP11 Single Dose Data at RANZCO

25 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

22 October 24

Interim Update on Progress in RP11 Repeat Dose Trials

×

Interim Update on Progress in RP11 Repeat Dose Trials

21 October 24

US FDA Grants Orphan Drug Designation to PYC Drug Candidate

×

US FDA Grants Orphan Drug Designation to PYC Drug Candidate

21 October 24

Trading Halt

×

Trading Halt

14 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

09 October 24

Annual Report to shareholders

×

Annual Report to shareholders

09 October 24

2024 Corporate Governance Statement & Appendix 4G

×

2024 Corporate Governance Statement & Appendix 4G

26 September 24

E&P Healthcare Conference Presentation

×

E&P Healthcare Conference Presentation

PYC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.07 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.07 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 24.1 -62.9 -36.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.06 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.07 -0.08 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 10.7 -62.9 -21.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -10.7 -13.9 -8.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.12 0.08 0.17 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.11 0.07 0.16 Lock Lock Lock
     Growth % Lock Lock Lock Lock -27.9 -37.3 141.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 322 325 394 Lock Lock Lock
Basic m Lock Lock Lock Lock 322 325 394 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 29 38 59 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.9 -5.1 -21.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -29 -38 -59 Lock Lock Lock
     Growth % Lock Lock Lock Lock -38.5 -30.3 -55.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -30 -39 -60 Lock Lock Lock
     Growth % Lock Lock Lock Lock -38.4 -29.6 -54.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -30 -39 -56 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -16 -16 -18 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -14 -23 -38 Lock Lock Lock
     Growth % Lock Lock Lock Lock 22.0 -64.4 -65.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -22 -24 -39 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 33 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 11 90 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -22 -25 -39 Lock Lock Lock
     Growth % Lock Lock Lock Lock -79.0 -12.4 -56.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 29 16 67 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 45 37 91 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -28 -15 -66 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 5 9 10 Lock Lock Lock
Equity $m Lock Lock Lock Lock 39 28 80 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 40 28 81 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25.3 -30.3 191.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -30.6 -61.3 -41.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -35.2 -82.1 -46.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -63.1 -112.0 -108.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -29.6 -67.1 -69.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -46.5 -71.9 -70.7 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -901.0 -1,402.9 -1,206.2 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.0 0.4 1.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -71.6 -55.0 -81.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.9 3.8 9.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.9 3.8 9.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 74.2 48.9 78.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -496.4 -290.5 -423.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -30.6 -61.3 -41.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.3 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -35.2 -82.1 -46.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -35.2 -82.1 -46.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,069.8 1,550.6 2,127.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,069.8 -1,550.6 -2,127.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.11%

Value ($M)

1

Prior Change

N/A

7 Day Change

0.10%

1 Month Change

0.10%

3 Month Change

0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PYC Shortsell

Frequently Asked Questions

The current share price of PYC Therapeutics Limited (PYC:ASX) is AU$1.39.
The 52-week high share price for PYC Therapeutics Limited (PYC:ASX) is AU$2.10.
The 52-week low share price for PYC Therapeutics Limited (PYC:ASX)? is AU$0.72.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) has a franking level of 0.0%.
PYC Therapeutics Limited (PYC:ASX) is classified in the Healthcare.
The current P/E ratio for PYC Therapeutics Limited (PYC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.